RHX 829
Alternative Names: RHX-829Latest Information Update: 01 Apr 2021
At a glance
- Originator Rheos Medicines
- Class Anti-inflammatories; Antirheumatics
- Mechanism of Action T lymphocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Inflammatory bowel diseases; Rheumatoid arthritis
Most Recent Events
- 10 Mar 2021 Early research in Inflammatory bowel diseases in USA (unspecified route) before March 2021 (Rheos Medicines pipeline, March 2021)
- 10 Mar 2021 Early research in Rheumatoid arthritis in USA (unspecified route) before March 2021 (Rheos Medicines pipeline, March 2021)